



Publikationsliste - Prof. Dr. C. Bremer:

Originalarbeiten, Übersichtsartikel und Fallberichte

1. **Bremer C**, Bradford B U, Hunt K J, Knecht K T, Connor H D, Mason R P, Thurman R G
Role of Kupffer cells in the pathogenesis of hepatic reperfusion injury
Am J Physiol 267 (30), G630 - G636 (1994)
2. Spiegel H U, **Bremer C**, Boin C
Reduction of hepatic reperfusion injury by indomethacin mediated vasoconstriction:
A rat model with temporary splenocaval shunt
J Invest Surg. 8, 363-369 (1995)
3. **Bremer C**, Allkemper T, Reimer P, Rummeny E J, Spiegel H U, Peters P
Contrast enhanced MRI with intracellular contrast agents –
A new way of monitoring
hepatic reperfusion injury?
Transplant Proc 27 (5), 2884-2885 (1995)
4. Spiegel H U, Oldhafer K, Lang W, Schüttler W, **Bremer C**, Pichlmayr R
Beneficial effect of PAF antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation
Transplant Proc 27 (5), 2849-2851 (1995)
5. Reimer P, Allkemper T, **Bremer C**, Rummeny E J, Spiegel H U, Balzer T, Peters P E
Assessment of reperfusion injury by means of MR contrast agents in rat liver
JMRI 7, 490-494 (1997)
6. **Bremer C**, Schaefer R M
Heterozygosity for factor V Leiden in a haemodialysis patient with recurrent shunt thrombosis
Nephrol Dial Transplant 12 (8), 1775-1776 (1997)
7. Kribben A, **Bremer C**, Fritschka E, Koeppen S, Ahrens O, Philipp T
Ambulatory infusion of noradrenaline for long-term treatment of Shy-Drager syndrome
Kidney Blood Press Res 21 (1), 70-3 (1998)
8. **Bremer C**, Allkemper Th, Menzel J, Sulkowski U, Rummeny E, Reimer P
Preliminary clinical experience with laser-induced interstitial thermotherapy in patients with hepatocellular carcinoma
JMRI 8, 235-239 (1998)
9. Reimer P, **Bremer C**, Horch C, Morgenroth C, Allkemper T, Schuierer G
MR-Monitored LITT as a palliative concept in patients with high grade gliomas:
Preliminary clinical experience
JMRI 8, 240-244 (1998)
10. Cullen P, Söffker J, Höpfl M, **Bremer C**, Schlaghecken R, Mehrens T, Assmann G, Schäfer RM.
Hypochromic red cells and reticulocyte haemoglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis
Nephrol Dial Transplant 14 (3), 659-65 (1999)



11. Franzius C, Sciuk J, **Bremer C**, Kempkes M, Schober O
Determinaton of extent and activity in Erdheim-Chester disease
Clin Nucl Med 24 (4), 252-55 (1999)
12. **Bremer C**, Allkemper T, Bärmig J, Reimer P
RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography
JMRI 10 (3), 461-7 (1999)
13. Tombach B, Reimer P, Prumer B, Allkemper T, **Bremer C**, Muhler A, Heindel W
Does a higher concentration of gadolinium chelates improve first-pass cardiac signal changes?
JMRI 10 (5), 806-12 (1999)
14. Tombach B, **Bremer C**, Reimer P, Schaefer RM, Ebert W, Geens V, Heindel W
Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure
Invest Radiol 35 (1), 35-40 (2000)
15. **Bremer C**, Weissleder R
In vivo imaging of gene expression: MR and optical technologies
Acad Radiol 8, 15-23 (2001)
16. **Bremer C**, Ntziachristos V, Mahmood U, Tung C-H, Weissleder R
Fortschritte in der optischen Bildgebung
Radiologe 41 (2), 131-137 (2001)
17. **Bremer C**, Bogdanov A, Weissleder R
Bildgebung von Angiogenese
Radiologe 41 (2), 138-145 (2001)
18. Filler T, **Bremer C**, Peuker E, Bankert J, Kreft G, Reimer P
Hepatomorphologie der Laser-induzierten interstitiellen Thermotherapie
Radiologe 41 (2), 181-186 (2001)
19. **Bremer C**, Tung C, Weissleder R
In vivo molecular target assessment of matrix metalloproteinase inhibition
Nature Medicine 7 (6), 743-48 (2001)
20. Tombach B, **Bremer C**, Reimer, Kisters K, Schaefer RM, Geens, W, Heindel W
Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: Results of a randomized study
Radiology 218 (3), 651-7 (2001)
21. Wunderbaldinger P, **Bremer C**, Matuszewski L, Marten K, Turetschek K, Rand T
Efficient radiological assessment of the internal snapping hip syndrome
Eur Radiol 11(9), 1743-7 (2001)
22. **Bremer C**, Kreft G, Roggan A, Filler T, Reimer P
Ex vivo evaluation of novel miniaturized LITT-applicators for effective small volume tissue ablation
Invest Radiol 36 (6), 32-34 (2001)



23. **Bremer C**, Bredow S, Mahmood U, Weissleder R, Tung CH
Optical imaging of Matrix Metalloproteinase-2 activity in tumors:
Feasibility study in a mouse model
Radiology 221 (2), 523-9 (2001)
24. **Bremer C**, Tung C-H, Bogdanov A, Weissleder R
Imaging of differential protease expression in breast cancers for detection
of aggressive tumor phenotypes
Radiology 222 (3), 814-8 (2002)
25. **Bremer C**, Kreft G, Filler T, Reimer P
Accuracy of non-enhanced MRI to monitor histological lesion size during laser-induced
interstitial thermotherapy
Eur Radiol 12 (1), 237-44 (2002)
26. Allkemper T, **Bremer C**, Matuszewski L, Ebert W, Reimer P
Contrast-enhanced blood pool MRA with optimized iron oxides: Effect of size,
relaxivity, and dose on vascular contrast enhancement
Radiology 223 (2), 432-8 (2002)
27. Wunderbaldinger P, Josephson L, **Bremer C**, Moore A, Weissleder R
Detection of lymph node micrometastases by LCDIO enhanced MR imaging
Magnetic Resonance in Medicine 47 (2), 292-7 (2002)
28. Tombach B, **Bremer C**, Reimer, Kisters K, Schaefer RM, Geens, W, Heindel W
Using highly concentrated gadobutrol as an MR contrast agent in patients also
requiring hemodialysis: safety and dialysability
Am J Roentgenol 178 (1), 105-9 (2002)
29. Wunderbaldinger P, **Bremer C**, Schellenberger E, Cejna M, Turetschek K, Kainberger
Imaging features of iliopsoas bursitis
Eur Radiol 12 (2), 409-15 (2002)
30. Marten K, **Bremer C**, Khazaie K, Tung C-H, Weissleder R
Detection of dysplastic intestinal adenomas using enzyme sensing molecular beacons
Gastroenterology 122 (2), 406-14 (2002)
31. Ntziachristos V, Tung C-H, **Bremer C**, Weissleder R
Fluorescence-mediated tomography resolves protease activity in vivo
Nature Medicine 8 (7), 757-60 (2002)
32. Bogdanov A, Matuszewski L, **Bremer C**, Petrovsky A, Weissleder R
Oligomerization of paramagnetic substrates result in signal amplification and can be
used for MR imaging of molecular targets
Mol Imaging 1 (1), 16-23 (2002)
33. Ntziachristos V, **Bremer C**, Graves EE, Weissleder R
In-vivo tomographic imaging of near-infrared fluorescent probes
Mol Imaging 1 (2), 82-88 (2002)
34. Ntziachristos V, **Bremer C**, Tung C, Weissleder R.
Imaging cathepsin B up-regulation in HT-1080 tumor models using fluorescence-
mediated molecular tomography (FMT).
Acad Radiol 9 Suppl 2:S323-5 (2002)



35. **Bremer C**, Tung CH, Weissleder R
Molecular imaging of MMP expression and therapeutic MMP inhibition.
Acad Radiol 9 Suppl 2:S314-5 (2002)
36. **Bremer C**, Mustafa M, Bogdanov A, Ntziachristos V, Petrovsky A, Weissleder R
Steady state blood volume measurements in experimental tumors differing in angiogenic burden
Radiology, 226(1):214-20 (2003)
37. Ntziachristos V, **Bremer C**, Weissleder R
Fluorescence imaging with near infrared-light: new technological advances that enable in-vivo molecular imaging
Eur Radiol, 13(1):195-208 (2003)
38. **Bremer C**, Ntziachristos V, Weissleder R
Optical based Molecular Imaging: Contrast agents and potential medical applications
Eur Radiol, 13(2):231-43 (2003)
39. Kugel H, **Bremer C**, Puschel M, Fischbach R, Lenzen H, Tombach B, Van Aken H, Heindel W
Hazardous situation in the MR bore: induction in ECG leads causes fire.
Eur Radiol. 13(4):690-4 (2003)
40. Wunderbaldinger P, Turetschek K, **Bremer C**
Near-infrared fluorescence imaging of lymph nodes using a new enzyme sensing activatable macromolecular optical probe.
Eur Radiol. 13(9): 2206-2211 (2003)
41. Reimer P, **Bremer C**, Allkemper T, Engelhardt M, Mahler M, Ebert W, Tombach B
Myocardial Perfusion and MR Angiography of Chest with SH U 555 C: Results of Placebo-controlled Clinical Phase I Study.
Radiology 231(2): 474-81 (2004)
42. Tombach B, Reimer P, **Bremer C**, Allkemper T, Engelhardt M, Mahler M, Ebert W, Heindel W
First pass- and equilibrium- MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): Results of a human pilot study
NMR Biomed, 2004 Nov;17(7):500-6.
43. Matuszewski L, Persigehl T, Wall A, Schwindt W, Tombach B, Fobker M, Poremba C, Ebert W, Heindel W, **Bremer C**
Cell Tagging with clinically approved iron oxides: Feasibility and effect of lipofection, particle size and surface coating on labeling efficiency
Radiology, 235(1): 155-61 (2005)
44. Persigehl T, Heindel W, **Bremer C**
MR and optical approaches to Molecular Imaging
Abdom Imaging, 30(3):342-54 (2005)
45. Juergens KU, Reimer P, Weber TP, Tombach B, **Bremer C**, Renger B, van Aken H, Heindel W
Cine and tagged magnetic resonance imaging in short-term stunned versus necrotic myocardium?
Int J Cardiovasc Imaging , 21(2-3) 271-82 (2005)



46. **Bremer C**, Bankert J, Filler T, Tombach B, Ebert W, Reimer P
High-dose Gd-DTPA versus Gd-mesoporphyrin for postinterventional monitoring of LITT-induced tissue necrosis
JMRI, 21(6), 801-8 (2005)
47. **Bremer C**, Ntziachristos V, Weitkamp B, Theilmeier G, Heindel W, Weissleder R
Optical imaging of spontaneous breast tumors using protease sensing 'smart' optical contrast agents
Invest Radiol 40(6): 321-7 (2005)
48. Kessler T, Bieker R, Padró T, Schwöppe C, Persigehl T, **Bremer C**, Kreuter M, Berdel W, Mesters R
Inhibition of Tumor Growth by RGD Peptide Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature
Clicn Cancer Res, 11:6317-6324 (2005)
49. Höltnke C, Law M, Wagner S, Breyholz H-J, Kopka K, **Bremer C**, Schober O, Schäfers
Synthesis, in vitro pharmacology and biodistribution studies of new PD 156707derived ET_A receptor radioligands
Bioorg Med Chem, 14:1910-1917 (2006)
50. Albrecht O, Serve H, Tchinda J, Büchner T, **Bremer C**, Parwaresch R, Berdel WE
Acute Myeloid Leukemia presenting with a Uterus Tumor
Ann Hematol, 85:58-59 (2006)
51. Matuszewski L, Persigehl T, Wall A, Meier N, Bieker R, Kooijmann H, Tombach B, Mester R, Berdel W, Heindel W, **Bremer C**
Assessment of Bone Marrow Angiogenesis in patients with Acute Myeloid Leukaemia by Contrast Enhanced MRI with clinically approved iron oxides
Radiology, 242:217-224 (2007)
52. Von Wallbrunn A, Holtke C, Zuhlsdorf M, Heindel W, Schafers M, **Bremer C**
In vivo imaging of integrin $\alpha_5\beta_1$ expression using fluorescence-mediated tomography
Eur J Nucl Med Mol Imaging, 34:745-754 (2007)
53. Matuszewski L, Tombach B, Heindel W, **Bremer C**
Molekulare und parametrische Bildgebung mit Eisenoxiden
Radiologe, 47:34-42 (2007)
54. Holtke C, Von Wallbrunn AV, Kopka K, Schober O, Heindel W, Schäfers M, **Bremer C**
A Fluorescent Photoprobe for the Imaging of Endothelin Receptors.
Bioconjug Chem, 18(3):685-94 (2007)
55. Kuhlperter R, Dahnke H, Matuszewski L, Persigehl T, von Wallbrunn A, Allkemper T, Heindel W, Schaeffter T, **Bremer C**
R₂/R₂* mapping for sensing cell bound superparamagnetic nanoparticles
Radiology, 245(2):449-57 (2007)
56. Persigehl T, Bieker R, Matuszewski L, Wall A, Kessler T, Kooijman H, Meier N, Ebert Berdel W, Heindel W, Mesters RM, **Bremer C**
Early, non-invasive monitoring of anti-angiogenic tumor treatment by USPIO enhanced MRI in mice
Radiology, 244(2):449-56 (2007)



57. Persigehl T, Matuszewski L, Kessler T, Wall A, Meier N, Ebert W, Berdel W, Heindel W, Mesters RM, **Bremer C**
Prediction of anti-angiogenic treatment efficacy by iron oxide enhanced parametric MRI
Inv Radiol, 42(12):791-6 (2007)
58. Thoennissen NH, Schliemann C, Brunnberg U, Schmidt E, Staebler A, Stegger L, **Bremer C**, Schleicher C, Mesters RM, Müller-Tidow C, Berdel WE.
Chemotherapy in metastatic malignant triton tumor: report on two cases.
Oncol Rep. 18(4):763-7 (2007)
59. Stelljes M, Hermann S, Albring J, Kohler G, Loffler M, Franzius C, Poremba C, Schlosser V, Volkmann S, Opitz C, **Bremer C**, Kucharzik T, Silling G, Schober O, Berdel WE, Schäfers M, Kienast J.
Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction and monitoring of treatment efficiency by positron emission tomography
Blood, 1;111(5):2909-18 (2008)
60. Wall A, Persigehl T, Hauff P, Licha K, Schirner M, Müller SA, von Wallbrunn A, Matuszewski L, **Bremer C**
Differentiation of angiogenic burden in human breast cancer xenografts using a new perfusion type optical contrast agent (SIDAG)
Breast Cancer Res, 10;10(2):R23 (2008)
61. Von Wallbrunn A, Waldeck J, Hoeltke C, Zühlsdorf M, Heindel W, Schäfers M, **Bremer C**
In vivo optical imaging of CD13/APN - expression in tumor xenografts
J Biomed Opt, 13(1):011007 (2008)
62. Faust A, Waschkau B, Waldeck J, Breyholz HJ, Kopka K, Heindel W, Schäfers M, **Bremer C**
Synthesis and Evaluation of a Novel Fluorescent Photoprobe for Imaging Matrix Metalloproteinases MMP-2 and MMP-9; Bioconjug Chem. 2008 May;19(5):1001-8.
63. Sutton E, Henning T, Pichler B, **Bremer C**, Daldrup-Link HE
Cell Tracking with Optical Imaging
Eur Radiol. 2008 8(10):2021-32
64. Buerke B, Allkemper T, Kugel H, **Bremer C**, Evers S, Kooijman H, Heindel W, Tombach B
Qualitative and quantitative analysis of routinely postprocessed (CLEAR) CE-MRA data sets: Are SNR and CNR calculations reliable?
Acad Radiol, 2008 Sep;15(9):1111-7
65. Waldeck J, Häger F, Hölte C, Lanckohr C, von Wallbrunn A, Torsello G, Heindel W, Theilmeier G, Schäfers M, **Bremer C**
Near infrared fluorescence imaging of atherosclerotic plaques using an alpha(v)beta(3)-integrin targeted fluorochrome,
J Nucl Med. 2008 Nov;49(11):1845-51
66. Hölte C, Greese S, Waldeck J, Kopka K, Heindel W, Schäfers M, **Bremer C**
Biodistribution of a nonpeptidic fluorescent endothelin A receptor imaging probe.
Mol Imaging. 2009 Jan-Feb;8(1):27-34



67. Bieker R, Kessler T, Schwöppe C, Padro T, Perisgehl T, **Bremer C**, Dreischalück J, Kolkmeier A, Heindel W, Mesters RM, Berdel WE
Blood. 2009 May 14;113(20):5019-27
68. Herrmann E, Tiemann A, Eltze E, Bolenz C, **Bremer C**, Perisgehl T, Hertle L, Wülfing C
Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model.
J Cancer Res Clin Oncol. 2009; 135(10):1455-62
69. Faust A, Waschkau B, Waldeck J, Höltke C, Breyholz HJ, Wagner S, Kopka K, Schober O, Heindel W, Schäfers M, **Bremer C**.
Synthesis and Evaluation of a Novel Hydroxamate Based Fluorescent Photoprobe for Imaging of Matrix Metalloproteinases.
Bioconjug Chem. 2009 May 20;20(5):904-12.
70. Eisenblätter M, Ehrchen J, Varga G, Sunderkötter C, Heindel W, Roth J, **Bremer C**, Wall A.
In vivo optical imaging of cellular inflammatory response in granuloma formation using fluorescence-labeled macrophages.
J Nucl Med. 2009 Oct;50(10):1676-82. Epub 2009 Sep 16.
71. Höltke C, Law MP, Wagner S, Kopka K, Faust A, Breyholz HJ, Schober O, **Bremer C**, Riemann B, Schäfers M.
PET-compatible endothelin receptor radioligands: synthesis and first in vitro and in vivo studies.
Bioorg Med Chem. 2009 Oct 15;17(20):7197-208.
72. Bunck AC, Engelen MA, Schnackenburg B, Furkert J, **Bremer C**, Heindel W, Stypmann J, Maintz D.
Feasibility of functional cardiac MR imaging in mice using a clinical 3 Tesla whole body scanner.
Invest Radiol. 2009 Dec;44(12):749-56.
73. Höltke C, Faust A, Breyholz HJ, Kopka K, Schober O, Riemann B, **Bremer C**, Schäfers M, Wagner S.
Non-invasive approaches to visualize the endothelin axis in vivo using state-of-the-art molecular imaging modalities.
Mini Rev Med Chem. 2009 Dec;9(14):1580-95. Review.
74. Schwöppe C, Kessler T, Persigehl T, Liersch R, Hintelmann H, Dreischalück J, Ring J, **Bremer C**, Heindel W, Mesters RM, Berdel WE.
Tissue-factor fusion proteins induce occlusion of tumor vessels.
Thromb Res. 2010 Apr;125 Suppl 2:S143-50.
75. Persigehl T, Wall A, Kellert J, Ring J, Remmele S, Heindel W, Dahnke H, **Bremer C**.
Tumor blood volume determination by using susceptibility-corrected DeltaR2* multiecho MR.
Radiology. 2010 Jun;255(3):781-9.
76. Eisenblätter M, Höltke C, Persigehl T, **Bremer C**.
Optical techniques for the molecular imaging of angiogenesis.
Eur J Nucl Med Mol Imaging. 2010 Aug;37 Suppl 1:S127-37. Review



77. Larmann J, Frenzel T, Hahnenkamp A, Herzog C, Lorenz A, Steinbicker AU, Calmer S, Harendza T, Schmitz M, Echtermeyer F, Hildebrand R, **Bremer C**, Theilmeier G.
In vivo fluorescence-mediated tomography for quantification of urokinase receptor-dependent leukocyte trafficking in inflammation.
Anesthesiology. 2010 Sep;113(3):610-8.
78. Remmele S, Ring J, Sénégas J, Heindel W, Mesters RM, **Bremer C**, Persigehl T.
Concurrent MR blood volume and vessel size estimation in tumors by robust and simultaneous $\Delta R(2)$ and $\Delta R(2)^*$ quantification.
Magn Reson Med. 2011 Jul;66(1):144-53
79. Ring J, Persigehl T, Remmele S, Heindel W, Dahnke H, **Bremer C**.
Monitoring of Bevacizumab-Induced Antiangiogenic Treatment Effects By "Steady State" Ultrasmall Superparamagnetic Iron Oxide Particles Magnetic Resonance Imaging Using Robust Multiecho $\Delta R2^*$ Relaxometry.
Invest Radiol. 2011 May;46(5):326-30.
80. Poellinger A, Persigehl T, Mahler M, Bahner M, Ponder SL, Diekmann F, **Bremer C**, Moesta T. Near-infrared imaging of the breast using omocianine as a fluorescent dye: results of a placebo-controlled, clinical, multicenter trial.
Invest Radiol. 2011 Nov;46(11):697-704.
81. Büther K, Compeer MG, De Mey JG, Schober O, Schäfers M, **Bremer C**, Riemann B, Höltke C. Assessment of Endothelin-A Receptor Expression in Subcutaneous and Orthotopic Thyroid Carcinoma Xenografts in Vivo Employing Optical Imaging Methods.
Endocrinology. 2012 Jun;153(6):2907-18
82. Larmann J, Frenzel T, Schmitz M, Hahnenkamp A, Demmer P, Immenschuh S, Tietge U, **Bremer C**, Theilmeier G
In Vivo Fluorescence-mediated Tomography Imaging Demonstrates Atorvastatin Mediated Reduction of Lesion Macrophages in ApoE^{-/-} Mice.
Anesthesiology, im Druck
83. Hischemöller A, Walter C, Weiler V, Hummel H, Thepen T, Huhn M, Barth S, Hoheisel W, Köhler K, Dimova-Landen D, **Bremer C**, Haase M, Waldeck J Labeling of anti-MUC-1 binding single chain Fv fragments to surface modified upconversion nanoparticles for an in vivo molecular imaging proof of principle approach.
Int J Mol Sciences, 2012;13(4):4153-67
84. Neesse A, Hahnenkamp A, Griesmann H, Buchholz M, Hahn SA, Maghnouj A, Fendrich V, Ring J, Sipos B, Tuveson DA, **Bremer C**, Gress TM, Michl P
Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions
GUT, 2013 Jul;62(7):1034-43
85. Waschkau B, Faust A, Schäfers M, **Bremer C**
Performance of a new fluorescence-labeled MMP inhibitor to image tumor MMP activity in vivo in comparison to an MMP-activatable probe.
Contrast Media Mol Imaging. 2013 Jan-Feb;8(1):1-11
86. Larmann J, Frenzel T, Schmitz M, Hahnenkamp A, Demmer P, Immenschuh S, Tietge UJ, **Bremer C**, Theilmeier G
In vivo fluorescence-mediated tomography imaging demonstrates atorvastatin-mediated reduction of lesion macrophages in ApoE^{-/-} mice.
Anesthesiology. 2013 Jul;119(1):129-41.



87. Hahnenkamp A, Schäfers M, **Bremer C**, Höltke C.
Design and synthesis of small-molecule fluorescent photoprobes targeted to aminopeptidase N (APN/CD13) for optical imaging of angiogenesis.
Bioconjug Chem. 2013 Jun 19;24(6):1027-38
88. Persigehl T, Ring J, Budny T, Hahnenkamp A, Stoeppeler S, Schwartz LH, Spiegel HU, Heindel W, Remmele S, **Bremer C**.
Vessel size imaging (VSI) by robust magnetic resonance (MR) relaxometry: MR-VSI of solid tumors in correlation with immunohistology and intravital microscopy.
Mol Imaging. 2013 Oct;12(7):1-11.
89. Persigehl T, Ring J, **Bremer C**, Heindel W, Holtmeier R, Stypmann J, Claesener M, Hermann S, Schäfers M, Zerbst C, Schliemann C, Mesters RM, Berdel WE, Schwöppe C.
Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
Angiogenesis. 2014 Jan;17(1):235-46.
90. Hahnenkamp A, Alsibai W, **Bremer C**, Höltke C.
Optimizing the bioavailability of small molecular optical imaging probes by conjugation to an albumin affinity tag.
J Control Release. 2014 Jul 28;186:32-40.
91. Alsibai W, Hahnenkamp A, Eisenblätter M, Riemann B, Schäfers M, **Bremer C**, Haufe G, Höltke C.
Fluorescent non-peptidic RGD mimetics with high selectivity for $\alpha V\beta 3$ vs $\alpha IIb\beta 3$ integrin receptor: novel probes for in vivo optical imaging.
J Med Chem. 2014 Dec 11;57(23):9971-82.
92. Schmidt R, Nippe N, Strobel K, Masthoff M, Reifschneider O, Castelli DD, Höltke C, Aime S, Karst U, Sunderkötter C, **Bremer C**, Faber C.
Highly shifted proton MR imaging: cell tracking by using direct detection of paramagnetic compounds.
Radiology. 2014 Sep;272(3):785-95.
93. Vogl T, Eisenblätter M, Völler T, Zenker S, Hermann S, van Lent P, Faust A, Geyer C, Petersen B, Roebrock K, Schäfers M, **Bremer C**, Roth J
Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity.
Nat Commun. 2014 Aug 6;5:4593.
94. Stange R, Sahin H, Wieskötter B, Persigehl T, Ring J, **Bremer C**, Raschke MJ, Vieth V.
In vivo monitoring of angiogenesis during tendon repair: a novel MRI-based technique in a rat patellar tendon model.
Knee Surg Sports Traumatol Arthrosc. 2015 Aug;23(8):2433-9.
95. Becker A, Große Hokamp N, Zenker S, Flores-Borja F, Barzcyk K, Varga G, Roth J, Geyer C, Heindel W, **Bremer C**, Vogl T, Eisenblätter M.
Optical in vivo imaging of the alarmin S100A9 in tumor lesions allows for estimation of the individual malignant potential by evaluation of tumor-host cell interaction.
J Nucl Med. 2015 Mar;56(3):450-6.



96. Hillen J, Geyer C, Heitzmann M, Beckmann D, Krause A, Winkler I, Pavenstädt H, **Bremer C**, Pap T, Korb-Pap A.
Structural cartilage damage attracts circulating rheumatoid arthritis synovial fibroblasts into affected joints.
Arthritis Res Ther. 2017 Feb 28;19(1):40. doi: 10.1186/s13075-017-1245-9.
97. Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, GebSKI V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA.
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3.
98. Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, Findlay M, Robinson B, Jackson C, Strickland A, GebSKI V, Van Buskirk M, Zhao H, van Hazel G; SIRFLOX and FOXFIRE Global Trial Investigators.
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies.
Clin Colorectal Cancer. 2018 Dec;17(4):e617-e629. doi: 10.1016/j.clcc.2018.06.001. Epub 2018 Jun 12.
99. Höink A, Persigehl T, Kwecien R, Balthasar M, Mesters R, Berdel W, Heindel W, **Bremer C**, Schwöppe C.
Gadofosveset-enhanced MRI as simple surrogate parameter for real-time evaluation of the initial tumour vessel infarction by retargeted tissue factor tTF-NGR.
Oncol Lett. 2019 Jan;17(1):270-280. doi: 10.3892/ol.2018.9638. Epub 2018 Oct 29.



Buchbeiträge

1. **Bremer C**
Interventional MR
In: Reimer P, Parizel P M, Stichnoth F A: Clinical MR-Imaging - A Practical Approach. Springer Verlag, Heidelberg (1999)
2. **Bremer C**
Interventionelle MRT
In: Reimer P, Parizel P M, Stichnoth F A: Klinische MR-Bildgebung. Springer Verlag, Heidelberg (2000)
3. **Bremer C**
Abdomen - MR-gesteuerte Interventionen
In: Rummeny E, Reimer P, Heindel W: Ganzkörper MRT. Thieme Verlag, Heidelberg (2002)
4. **Bremer C**, Weissleder R
Magnetic Resonance Imaging at the mRNA and Protein Level.
In: Lorkowski S, Cullen P: Analyzing Gene Expression Wiley-VHC Verlag, Weinheim (2002)
5. **Bremer C**, Weissleder R
In Vivo Optical Imaging. In: Lorkowski S, Cullen P: Analyzing Gene Expression Wiley-VHC Verlag, Weinheim (2002)
6. **Bremer C**, Weissleder R
The role of nuclear medicine in relation to alternative modalities
In: Feinendegen LE, Shreeve WW, Bahk YW, Wagner Jr HN: Molecular Nuclear Medicine
The Challenge of genomics and proteomics to clinical practice
Springer Verlag, Heidelberg (2003)
7. **Bremer C**
Imaging of proteases for tumor detection and differentiation
In: Bogdanov A, Licha K
Ernst Schering Res Found Workshop 49: Molecular Imaging, an essential tool
inpreclinical research, diagnostic imaging and therapy
Springer Verlag, Heidelberg (2005)
8. Tombach B, Buerke B, Persigehl T, **Bremer C**
Kontrastmittel
In: Brambs HJ: Radiologie update ,04
MPM Verlag, Pohlheim (2004)
9. Wunder A, Kloh J, **Bremer C**
Molekulare Bildgebung mit optischen Methoden – Möglichkeiten und Grenzen
In: W. Niederlag (Dresden), H. U. Lemke (Berlin), W. Semmler (Heidelberg), **C. Bremer** (Münster)
Molecular Imaging – Innovationen und Visionen in der medizinischen Bildgebung
Health Academy, Dresden (2006)



10. Wall A, **Bremer C**
Optical imaging techniques for breast cancer
In: Hyat MA
Cancer imaging – lung and breast cancer
Elsevier Verlag, Amsterdam (2008)
11. **Bremer C**, Schäfers M
Targets
In: Bombardieri E, Buscombe J, Lucignani G, Schober O
Advances in Nuclear Oncology, (2009)
12. **Bremer C**
Molecular targets, Reporter systems, Molecular probes, optical probes
In: Baert A L
Encyclopedic Reference of Imaging, Springer Verlag, (2009)